On Thursday, Aurinia Pharmaceuticals Inc ( AUPH ) reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.

The biopharma company reported fourth-quarter sales of $59.9 million, up 33% year over year, almost in line with the consensus of $59.9 million.

Net product sales of LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis, were $57.6 million, up 36%.

License, collaboration, and royalty revenue, which includes manufacturing services revenue and royalties from Aurinia's collaboration partner, Otsuka, was $2.3 million, down 18%.

Also Read: Taiwan Semiconductor Faces Government Scrutiny on Overseas Ventures Amid Intel Stake Rumors

For 2024, net product sales were $216.2 million, up 36%, within the management guidance of $210 million-$220 million.

The company reported an operating loss of $1.67 million compared to $29.7 million a year ago.

Aurinia reported a net income of $1.43 million, better than the loss of $26.9 million.

Aurinia CEO Peter Greenleaf expects 2025 to be “an exciting year” for the company when it comes to increasing LUPKYNIS's adoption. Plans are also in place to advance AUR200, which has the potential to treat “a wide range of autoimmune diseases,” he adds.

Guidance: Aurinia expects fiscal year revenue of $250 million-$260 million versus the consensus of $274.4 million.

Price Action: Aurinia stock is down 6.35% at $7.45 at the last Thursday.

Read Next:

Hilton Grand Vacations Q4 Misses EPS Estimates, Boosts Share Repurchase

Image: Shutterstock